Funding from the Anthem-backed series E round will support the commercialisation of Sera's biomarker tests, which predict the chances of preterm births.
Sera Prognostics, a US-based provider of biomarker tests for pregnant women, closed a $100m series E round co-led by health benefits provider Anthem and investment firm Blue Ox Healthcare Partners yesterday.
The round included Vivo Capital, aMoon Fund, Parian Global Management and undisclosed additional backers, and it increased the company’s overall funding to $220m.
Founded in 2008, Sera has developed a blood-based biomarker test called PreTRM that can predict the chances of a singleton pregnancy resulting in a spontaneous preterm…
